Готові списки джерел за темами / Metabolomic signature

Добірка наукової літератури з теми "Metabolomic signature"

Автор: Grafiati
Опубліковано: 6 липня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Metabolomic signature".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій

Статті в журналах з теми "Metabolomic signature":

1

Szczerbinski, Lukasz, Gladys Wojciechowska, Adam Olichwier, Mark A. Taylor, Urszula Puchta, Paulina Konopka, Adam Paszko, et al. "Untargeted Metabolomics Analysis of the Serum Metabolic Signature of Childhood Obesity." Nutrients 14, no. 1 (January 4, 2022): 214. http://dx.doi.org/10.3390/nu14010214.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Obesity rates among children are growing rapidly worldwide, placing massive pressure on healthcare systems. Untargeted metabolomics can expand our understanding of the pathogenesis of obesity and elucidate mechanisms related to its symptoms. However, the metabolic signatures of obesity in children have not been thoroughly investigated. Herein, we explored metabolites associated with obesity development in childhood. Untargeted metabolomic profiling was performed on fasting serum samples from 27 obese Caucasian children and adolescents and 15 sex- and age-matched normal-weight children. Three metabolomic assays were combined and yielded 726 unique identified metabolites: gas chromatography–mass spectrometry (GC–MS), hydrophilic interaction liquid chromatography coupled to mass spectrometry (HILIC LC–MS/MS), and lipidomics. Univariate and multivariate analyses showed clear discrimination between the untargeted metabolomes of obese and normal-weight children, with 162 significantly differentially expressed metabolites between groups. Children with obesity had higher concentrations of branch-chained amino acids and various lipid metabolites, including phosphatidylcholines, cholesteryl esters, triglycerides. Thus, an early manifestation of obesity pathogenesis and its metabolic consequences in the serum metabolome are correlated with altered lipid metabolism. Obesity metabolite patterns in the adult population were very similar to the metabolic signature of childhood obesity. Identified metabolites could be potential biomarkers and used to study obesity pathomechanisms.
2

Bever, Alaina M., Dong Hang, Amit D. Joshi, Connor M. Geraghty, Dong Hoon Lee, Fred K. Tabung, Shuji Ogino, et al. "Abstract 3006: Metabolomic signatures of metabolic disturbance and inflammation in relation to colorectal cancer risk." Cancer Research 83, no. 7_Supplement (April 4, 2023): 3006. http://dx.doi.org/10.1158/1538-7445.am2023-3006.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract Background: Metabolic disturbance and inflammation may explain observed associations between higher body mass index (BMI) and increased risk of colorectal cancer (CRC); however, the underlying mechanisms are not fully understood. Objectives: We characterized individual plasma metabolites and metabolomic signatures of metabolic disturbance and inflammation and evaluated their association with prospective CRC risk within the Nurses’ Health Study and the Health Professionals Follow-up Study. Methods: Among 686 colorectal cancer cases and 686 age-matched controls, we used reduced rank regression of markers of metabolic disturbance (BMI, waist circumference, C-peptide, and adiponectin) or inflammation (BMI, C-reactive protein, interleukin-6, and tumor necrosis factor receptor superfamily member 1B) with cross-sectional measures of 353 plasma metabolites to develop a Y-score for metabolic disturbance and Y-score for inflammation among men and women separately. We then used elastic net regression to derive a signature of metabolites, and multiple linear regression to identify individual metabolites, associated with each Y-score. We evaluated the association of individual metabolites and the metabolomic signatures with odds of CRC using conditional logistic regression adjusted for other CRC risk factors. Results: The metabolomic signature of metabolic disturbance consisted of 41 metabolites selected via elastic net regression in men and 72 in women; the metabolomic signature of inflammation consisted of 68 metabolites in men and 119 in women. The metabolic disturbance metabolomic signatures captured, on average, 36% of variation in markers of metabolic disturbance in women and 35% in men; the inflammation signature captured 35% of variation in inflammatory markers in women and 26% in men. The metabolomic signature of metabolic disturbance was associated with increased odds of CRC (odds ratio (OR) comparing highest to lowest quartile = 1.63; 95% confidence interval (CI), 0.92, 2.91; Ptrend = 0.31) and the metabolomic signature of inflammation was associated with increased odds of CRC (OR = 2.01; 95% CI, 1.14, 3.57; Ptrend = 0.008) among men. Neither signature was associated with CRC among women. Of the metabolites associated with metabolic disturbance and inflammation, 13 metabolites were also associated with CRC: 4 metabolites classified as uremic toxins (2 purine nucleosides and 2 amino acid derivates); 3 sphingolipids; 3 glycerophospholipids; 2 sterols related to cholesterol homeostasis; and 3-ureidopropanoate, a uracil metabolism substrate. Conclusion: We identified plasma metabolomic signatures and individual metabolites associated with metabolic disturbance, inflammation, and CRC risk, highlighting pathways such as protein metabolism and lipid homeostasis that may relate adiposity-related metabolic disturbance and inflammation to CRC development. Citation Format: Alaina M. Bever, Dong Hang, Amit D. Joshi, Connor M. Geraghty, Dong Hoon Lee, Fred K. Tabung, Shuji Ogino, Jeffrey A. Meyerhardt, Andrew T. Chan, Edward L. Giovannucci, A. Heather Eliassen, Liming Liang, Meir J. Stampfer, Mingyang Song. Metabolomic signatures of metabolic disturbance and inflammation in relation to colorectal cancer risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3006.
3

Yang, Mingjia, Chen Zhu, Lingbin Du, Jianv Huang, Jiayi Lu, Jing Yang, Ye Tong, et al. "A Metabolomic Signature of Obesity and Risk of Colorectal Cancer: Two Nested Case–Control Studies." Metabolites 13, no. 2 (February 5, 2023): 234. http://dx.doi.org/10.3390/metabo13020234.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Obesity is a leading contributor to colorectal cancer (CRC) risk, but the metabolic mechanisms linking obesity to CRC are not fully understood. We leveraged untargeted metabolomics data from two 1:1 matched, nested case–control studies for CRC, including 223 pairs from the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and 190 pairs from a prospective Chinese cohort. We explored serum metabolites related to body mass index (BMI), constructed a metabolomic signature of obesity, and examined the association between the signature and CRC risk. In total, 72 of 278 named metabolites were correlated with BMI after multiple testing corrections (p FDR < 0.05). The metabolomic signature was calculated by including 39 metabolites that were independently associated with BMI. There was a linear positive association between the signature and CRC risk in both cohorts (p for linear < 0.05). Per 1-SD increment of the signature was associated with 38% (95% CI: 9–75%) and 28% (95% CI: 2–62%) higher risks of CRC in the US and Chinese cohorts, respectively. In conclusion, we identified a metabolomic signature for obesity and demonstrated the association between the signature and CRC risk. The findings offer new insights into the underlying mechanisms of CRC, which is critical for improved CRC prevention.
4

Davis, Vanessa Wylie, Dan E. Schiller, and Michael B. Sawyer. "Metabolomic signature of esophageal cancer." Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 21. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.21.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
21 Background: Esophageal cancer is a pervasive malignancy, and early detection combined with newer therapeutic targets could alter the landscape of this condition. Metabolomic profiling offers one such innovative opportunity. We applied metabolomic techniques to identify urinary metabolites uniquely associated with this condition. Methods: Urine samples from patients with histologically confirmed esophageal cancer (n=66) and healthy volunteers (n=25) were collected and examined using 1H-NMR spectroscopy. Targeted profiling of spectra using Chenomx NMR Suite 7.0 software permitted detection and quantification of 66 distinct metabolites. Unsupervised (principal component analysis, PCA) and supervised (partial least-squares discriminant analysis, PLS-DA) multivariate pattern recognition techniques were applied to discriminate between sample spectra of esophageal cancer patients and healthy volunteers using SIMCA-P (version 11, Umetrics, Umeå, Sweden). Results: Significant differences were found when comparing concentrations of 59 metabolites in urines of healthy volunteers and esophageal cancer patients. Those metabolites contributing most class discriminating information included choline, urea, 2-aminobutyrate, and 3-hydoxybutyrate. Clear distinctions between patients with esophageal cancer and healthy controls were noted when PLS-DA was applied to the data set. Model parameters for both goodness of fit R2, and predictive capability Q2, were high (R2 = 0.867; Q2 = 0.732). Model validity was tested using response permutation and results were suggestive of excellent predictive power (see Figure). Conclusions: Urinary metabolomics identified a discrete signature associated with esophageal cancer compared to healthy controls. This profile has the potential to aid in diagnosis and development of new therapeutic targets.
5

Lokhov, Petr G., Oxana P. Trifonova, Dmitry L. Maslov, and Elena E. Balashova. "In Situ Mass Spectrometry Diagnostics of Impaired Glucose Tolerance Using Label-Free Metabolomic Signature." Diagnostics 10, no. 12 (December 5, 2020): 1052. http://dx.doi.org/10.3390/diagnostics10121052.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
In metabolomics, mass spectrometry is used to detect a large number of low-molecular substances in a single analysis. Such a capacity could have direct application in disease diagnostics. However, it is challenging because of the analysis complexity, and the search for a way to simplify it while maintaining the diagnostic capability is an urgent task. It has been proposed to use the metabolomic signature without complex data processing (mass peak detection, alignment, normalization, and identification of substances, as well as any complex statistical analysis) to make the analysis more simple and rapid. Methods: A label-free approach was implemented in the metabolomic signature, which makes the measurement of the actual or conditional concentrations unnecessary, uses only mass peak relations, and minimizes mass spectra processing. The approach was tested on the diagnosis of impaired glucose tolerance (IGT). Results: The label-free metabolic signature demonstrated a diagnostic accuracy for IGT equal to 88% (specificity 85%, sensitivity 90%, and area under receiver operating characteristic curve (AUC) of 0.91), which is considered to be a good quality for diagnostics. Conclusions: It is possible to compile label-free signatures for diseases that allow for diagnosing the disease in situ, i.e., right at the mass spectrometer without complex data processing. This achievement makes all mass spectrometers potentially versatile diagnostic devices and accelerates the introduction of metabolomics into medicine.
6

Li, Zhen, Yue Mu, Chunlan Guo, Xin You, Xiaoyan Liu, Qian Li, and Wei Sun. "Analysis of the saliva metabolic signature in patients with primary Sjögren’s syndrome." PLOS ONE 17, no. 6 (June 2, 2022): e0269275. http://dx.doi.org/10.1371/journal.pone.0269275.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background The saliva metabolome has been applied to explore disease biomarkers. In this study we characterized the metabolic profile of primary Sjögren’s syndrome (pSS) patients and explored metabolomic biomarkers. Methods This work presents a liquid chromatography-mass spectrometry-based metabolomic study of the saliva of 32 patients with pSS and 38 age- and sex-matched healthy adults. Potential pSS saliva metabolite biomarkers were explored using test group saliva samples (20 patients with pSS vs. 25 healthy adults) and were then verified by a cross-validation group (12 patients with pSS vs. 13 healthy adults). Results Metabolic pathways, including tryptophan metabolism, tyrosine metabolism, carbon fixation, and aspartate and asparagine metabolism, were found to be significantly regulated and related to inflammatory injury, neurological cognitive impairment and the immune response. Phenylalanyl-alanine was discovered to have good predictive ability for pSS, with an area under the curve (AUC) of 0.87 in the testing group (validation group: AUC = 0.75). Conclusion Our study shows that salivary metabolomics is a useful strategy for differential analysis and biomarker discovery in pSS.
7

Stockard, Bradley, Timothy Garrett, Soheil Meshinchi, and Jatinder K. Lamba. "Metabolomic Profiling Defines Distinct Metabolic Signature Associated with FLT3/ITD AML." Blood 128, no. 22 (December 2, 2016): 1692. http://dx.doi.org/10.1182/blood.v128.22.1692.1692.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract AML is a hematological disorder resulting from proliferation and expansion of malignant myeloid cells. Clinical outcome for AML remains dismal despite intensive therapy in part due to the disease heterogeneity with various cytogenetic and molecular lesions. Fms-Like Tyrosine Kinase-3 (FLT3) is a receptor tyrosine kinase expressed hematopoietic stem/progenitor cells. Activating mutations of FLT3 gene due to internal tandem duplication of the juxtamembrane domain coding sequence (FLT3/ITD) causes autonomous cellular proliferations leading to disease progression. Metabolomic profiling has been successfully utilized to identify metabolic alterations in hematological disorders. However, no studies on metabolic alterations associated with pediatric AML have been reported at this time. In this study we propose to establish the metabolomic landscape in pediatric AML patients and identify differential expression of metabolites based on FLT3/ITD status. Cellular and plasma metabolomics profile was generated from 32 matching diagnostic material from 16 patients with and without FLT3/ITD (N=8 for each cohort and each sample was run in duplicate) treated on COG-AAML0531 study. Global metabolomics profiling was performed on a Thermo Q-Exactive Oribtrap mass spectrometer with Dionex UHPLC and autosampler. All samples were analyzed in duplicate in positive and negative heated electrospray ionization with a mass resolution of 35,000 at m/z 200 as separate injections. Separation was achieved on an ACE 18-pfp 100 x 2.1 mm, 2 µm column with mobile phase A as 0.1% formic acid in water and mobile phase B as acetonitrile. This is a polar embedded stationary phase that provides comprehensive coverage, but does have some limitation is the coverage of very polar species. The flow rate was 350 µL/min with a column temperature of 25¡C. 4 µL was injected for negative ions and 2 µL for positive ions. Statistical analysis was performed using MetaboAnalyst software using all metabolites (known and unknown) as well as only the annotated metabolites. Univariate analysis was performed by volcano plot and Multivariate analysis was performed using PCA, PLS-DA and OPLS-DA. Total of 2966 plasma metabolome (779 negative and 2187 positive) and 1742 (227 negative and 1515 positive) cellular metabolome features were identified. All subsequent data analyses were normalized to the sum of metabolites for each sample. Comparison of the cellular metabolome in patients with and without FLT3/ITD identified 12 known and 135 unknown metabolites that were significantly different between two cohorts (p<0.05). Similar comparison of the plasma metabolome identified19 known and 300 unknown metabolites in the patient with and without FLT3/ITD (top results are shown in Fig.1). Orthogonal partial least squares-discriminant analysis (OPLS-DA) showed clear separation between the 2 groups (Fig.2). Some of the top known plasma metabolites (p<0.01) differentiating patients by FLT3 status include guanine, pyrimidine-2-3dicarboxylate, acetylglycine, acetyl-L-alanine, aminobutonate gaba, L-carnitine, methyl-2 oxovaleric acid, asparagine, acetyl arginine, Hydroxydecanoic acid, cysteic acid and glycocholic acid. Within leukemic cells top metabolites differentiating between FLT3 status included actyly carnitine, adenosine monophosphate, hypoxanthine, diaminohepatanedioate, guanine and sphingosine. Metaboanalyst Pathway analysis module mapped the differentiating metabolites to aminoacyl-tRNA biosynthesis, Glycerophospholipid metabolism, Cysteine and methionine metabolism, Pantothenate and CoA biosynthesis, Purine metabolism. This pilot study defines distinct metabolomics signature associated with genomic subtype of AML (FLT3/ITD). As metabolomics provides an insight into the ultimate metabolic destination of normal and malignant hematopoiesis, it has a potential to provide a unique insight into the altered metabolic pathways in AML and identify pathways and networks that might be shared by varied genomic subtypes of AML. Such data can help merge rare genomic variants based on shared metabolic signatures and more appropriately guide directed therapies. Disclosures No relevant conflicts of interest to declare.
8

Serri, Orianne, Magalie Boguenet, Juan Manuel Chao de la Barca, Pierre-Emmanuel Bouet, Hady El Hachem, Odile Blanchet, Pascal Reynier, and Pascale May-Panloup. "A Metabolomic Profile of Seminal Fluid in Extremely Severe Oligozoopermia Suggesting an Epididymal Involvement." Metabolites 12, no. 12 (December 15, 2022): 1266. http://dx.doi.org/10.3390/metabo12121266.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Male infertility has increased in the last decade. Pathophysiologic mechanisms behind extreme oligospermia (EO) are not yet fully understood. In new “omics” approaches, metabolomic can offer new information and help elucidate these mechanisms. We performed a metabolomics study of the seminal fluid (SF) in order to understand the mechanisms implicated in EO. We realized a targeted quantitative analysis using high performance liquid chromatography and mass spectrometry to compare the SF metabolomic profile of 19 men with EO with that of 22 men with a history of vasectomy (V) and 20 men with normal semen parameters (C). A total of 114 metabolites were identified. We obtained a multivariate OPLS-DA model discriminating the three groups. Signatures show significantly higher levels of amino acids and polyamines in C group. The sum of polyunsaturated fatty acids and free carnitine progressively decrease between the three groups (C > EO > V) and sphingomyelins are significantly lower in V group. Our signature characterizing EO includes metabolites already linked to infertility in previous studies. The similarities between the signatures of the EO and V groups are clear evidence of epididymal dysfunction in the case of testicular damage. This study shows the complexity of the metabolomic dysfunction occurring in the SF of EO men and underlines the importance of metabolomics in understanding male infertility.
9

Putluri, N., Y. Zhang, V. Putluri, S. Vareed, V. T. Vasu, S. M. Fischer, C. Chad, and A. Sreekumar. "Androgen-regulated metabolome in prostate cancer." Journal of Clinical Oncology 29, no. 7_suppl (March 1, 2011): 25. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.25.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
25 Background: Prostate cancer (PC) is the second most prevalent cancer among American men which is primarily treated by androgen ablation therapy. Although a number of patients respond to this regimen, a significant subset fail and the tumor invariably progresses into a hormone refractory metastatic state, which is lethal. Earlier we had reported the first unbiased metabolomic signature for localized and metastatic prostate cancer tissues. Advancing further, we attempt to delineate the subset of metabolome in prostate cancer which is regulated by androgen-action. Methods: Androgen responsive (R22V1, LnCap and VCAP) and independent (PC3, DU145) PC cells and benign prostate epithelial cells (RWPE) were profiled for their metabolomic alterations using mass spectrometry. Extracted metabolome from these cells were profiles using a combination quadrupole-time-of-flight (Q-TOF) and triple quadrupole (QQQ) mass spectrometers coupled to reverse phase and aqueous normal phase chromatography. The metabolomic profiles were analyzed to delineate class-specific signatures which were interrogated for altered bioprocesses using Oncomine Concept Map (OCM, www.oncomine.org ). The androgen receptor (AR) regulated metabolome was verified using treatment of PC cells with synthetic androgen, R1881. Results: A total of 3,092 metabolites (113 named) were detected across the 4 cells lines, of which 869 compounds were significantly (ANOVA P<0.01) different between androgen responsive and non-responsive cells. The differential compendia included 28 named metabolites, including sarcosine which was earlier shown to be elevated during PC development and progression. Bioprocess mapping of AR-regulated metabolome revealed enrichment of amino acid metabolism and methylation potential, both of which were earlier defined to be the hallmarks of PC development and progression. Conclusions: The study defines AR-regulated metabolic signature which portrays enrichment of amino acid metabolism and methylation potential that are hallmarks of PC development and progression. No significant financial relationships to disclose.
10

Troisi, Jacopo, Laura Sarno, Annamaria Landolfi, Giovanni Scala, Pasquale Martinelli, Roberta Venturella, Annalisa Di Cello, Fulvio Zullo, and Maurizio Guida. "Metabolomic Signature of Endometrial Cancer." Journal of Proteome Research 17, no. 2 (January 2, 2018): 804–12. http://dx.doi.org/10.1021/acs.jproteome.7b00503.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел
Також вас можуть зацікавити розширені добірки на тему "Metabolomic signature" для конкретних типів джерел:
Статті в журналах Дисертації

Дисертації з теми "Metabolomic signature":

1

Rocha, Cláudia Manuela Mesquita da. "Metabolic signature of lung cancer: a metabolomic study of human tissues and biofluids." Doctoral thesis, Universidade de Aveiro, 2015. http://hdl.handle.net/10773/13957.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Doutoramento em Química
This thesis reports the application of metabolomics to human tissues and biofluids (blood plasma and urine) to unveil the metabolic signature of primary lung cancer. In Chapter 1, a brief introduction on lung cancer epidemiology and pathogenesis, together with a review of the main metabolic dysregulations known to be associated with cancer, is presented. The metabolomics approach is also described, addressing the analytical and statistical methods employed, as well as the current state of the art on its application to clinical lung cancer studies. Chapter 2 provides the experimental details of this work, in regard to the subjects enrolled, sample collection and analysis, and data processing. In Chapter 3, the metabolic characterization of intact lung tissues (from 56 patients) by proton High Resolution Magic Angle Spinning (HRMAS) Nuclear Magnetic Resonance (NMR) spectroscopy is described. After careful assessment of acquisition conditions and thorough spectral assignment (over 50 metabolites identified), the metabolic profiles of tumour and adjacent control tissues were compared through multivariate analysis. The two tissue classes could be discriminated with 97% accuracy, with 13 metabolites significantly accounting for this discrimination: glucose and acetate (depleted in tumours), together with lactate, alanine, glutamate, GSH, taurine, creatine, phosphocholine, glycerophosphocholine, phosphoethanolamine, uracil nucleotides and peptides (increased in tumours). Some of these variations corroborated typical features of cancer metabolism (e.g., upregulated glycolysis and glutaminolysis), while others suggested less known pathways (e.g., antioxidant protection, protein degradation) to play important roles. Another major and novel finding described in this chapter was the dependence of this metabolic signature on tumour histological subtype. While main alterations in adenocarcinomas (AdC) related to phospholipid and protein metabolisms, squamous cell carcinomas (SqCC) were found to have stronger glycolytic and glutaminolytic profiles, making it possible to build a valid classification model to discriminate these two subtypes. Chapter 4 reports the NMR metabolomic study of blood plasma from over 100 patients and near 100 healthy controls, the multivariate model built having afforded a classification rate of 87%. The two groups were found to differ significantly in the levels of lactate, pyruvate, acetoacetate, LDL+VLDL lipoproteins and glycoproteins (increased in patients), together with glutamine, histidine, valine, methanol, HDL lipoproteins and two unassigned compounds (decreased in patients). Interestingly, these variations were detected from initial disease stages and the magnitude of some of them depended on the histological type, although not allowing AdC vs. SqCC discrimination. Moreover, it is shown in this chapter that age mismatch between control and cancer groups could not be ruled out as a possible confounding factor, and exploratory external validation afforded a classification rate of 85%. The NMR profiling of urine from lung cancer patients and healthy controls is presented in Chapter 5. Compared to plasma, the classification model built with urinary profiles resulted in a superior classification rate (97%). After careful assessment of possible bias from gender, age and smoking habits, a set of 19 metabolites was proposed to be cancer-related (out of which 3 were unknowns and 6 were partially identified as N-acetylated metabolites). As for plasma, these variations were detected regardless of disease stage and showed some dependency on histological subtype, the AdC vs. SqCC model built showing modest predictive power. In addition, preliminary external validation of the urine-based classification model afforded 100% sensitivity and 90% specificity, which are exciting results in terms of potential for future clinical application. Chapter 6 describes the analysis of urine from a subset of patients by a different profiling technique, namely, Ultra-Performance Liquid Chromatography coupled to Mass Spectrometry (UPLC-MS). Although the identification of discriminant metabolites was very limited, multivariate models showed high classification rate and predictive power, thus reinforcing the value of urine in the context of lung cancer diagnosis. Finally, the main conclusions of this thesis are presented in Chapter 7, highlighting the potential of integrated metabolomics of tissues and biofluids to improve current understanding of lung cancer altered metabolism and to reveal new marker profiles with diagnostic value.
A presente tese reporta a aplicação da metabolómica ao estudo de tecidos e biofluidos humanos (plasma sanguíneo e urina), com o intuito de caracterizar a assinatura metabólica do cancro pulmonar primário. No Capítulo 1, apresenta-se uma breve introdução sobre a epidemiologia e a patogénese deste tipo de cancro, bem como um sumário das principais alterações metabólicas tipicamente associadas ao cancro em geral. Descreve-se ainda a abordagem metabolómica, nomeadamente os métodos analíticos e estatísticos utilizados, assim como o estado da arte da sua aplicação em estudos clínicos do cancro do pulmão. No Capítulo 2, apresentam-se os detalhes experimentais deste trabalho, no que diz respeito ao grupo de indivíduos envolvidos, à colheita e análise das amostras e ao posterior tratamento dos dados. O Capítulo 3 descreve a caracterização metabólica de tecidos do pulmão (de 56 doentes) por espetroscopia de Ressonância Magnética Nuclear (RMN) de alta resolução com rotação no ângulo mágico. Após a otimização cuidada das condições de aquisição e a identificação detalhada dos sinais espetrais (mais de 50 metabolitos identificados), os perfis metabólicos dos tumores e dos tecidos adjacentes não envolvidos (controlos) foram comparados por análise multivariada, tendo sido discriminados com uma exatidão de 97%. Os metabolitos que mais significativamente contribuíram para esta diferenciação foram: glucose e acetato (diminuídos nos tumores), lactato, alanina, glutamato, GSH, taurina, creatina, fosfocolina, glicerofosfocolina, fosfoetanolamina, nucleótidos de uracilo e péptidos (aumentados nos tumores). Algumas destas variações corroboraram alterações típicas do metabolismo do cancro (e.g., glicólise e glutaminólise aumentadas), enquanto outras sugeriram novas pistas sobre a possível relevância de processos como a proteção antioxidante e a degradação proteica. Um outro resultado novo e importante descrito neste capítulo foi a dependência da assinatura metabólica em relação ao tipo histológico do tumor. Enquanto as principais alterações observadas nos adenocarcinomas (AdC) se relacionaram com o metabolismo fosfolipídico e proteico, os carcinomas de células escamosas (SqCC) apresentaram perfis glicolíticos e glutaminolíticos mais pronunciados, sendo possível construir um modelo válido para a discriminação destes subtipos. No Capítulo 4, apresenta-se o estudo metabolómico por RMN de plasma sanguíneo de mais de 100 doentes e quase 100 controlos saudáveis, do qual resultou um modelo multivariado com uma taxa de classificação de 87%. A distinção entre os grupos foi feita essencialmente com base nos níveis de lactato, piruvato, acetoacetato, lipoproteínas LDL+VLDL e glicoproteínas (aumentados nos doentes), juntamente com os níveis de glutamina, histidina, valina, metanol, lipoproteínas HDL e dois compostos não identificados (diminuídos nos doentes). Estas variações foram detetadas desde os estádios iniciais da doença e a magnitude de algumas delas dependeu do tipo histológico, embora não permitindo discriminar AdC de SqCC. Para além disso, mostra-se neste capítulo que o desequilíbrio dos grupos controlo e cancro em termos da idade dos indivíduos poderá ter alguma influência nos resultados, e apresenta-se uma tentativa exploratória de validação externa, que resultou numa taxa de classificação de 85%. O estudo por RMN do perfil metabólico da urina dos doentes com cancro do pulmão e dos controlos é apresentado no Capítulo 5. Comparativamente ao plasma, o modelo construído com os perfis urinários apresentou uma taxa de classificação superior (97%). Após uma avaliação cuidada da possível influência do género, idade e hábitos tabágicos, um conjunto de 19 metabolitos foi proposto como estando relacionado com a doença (incluindo 3 compostos desconhecidos e 6 parcialmente identificados como metabolitos N-acetilados). Tal como no caso do plasma, estas variações foram detetadas em doentes no estádio inicial e mostraram alguma dependência em relação ao tipo histológico, obtendo-se um modelo válido para a discriminação AdC vs. SqCC, ainda que com um poder preditivo modesto. Para além disso, o teste preliminar de validação externa revelou 100% de sensibilidade e 90% de especificidade, o que é um resultado bastante promissor em termos da potencial utilização dos perfis urinários em aplicações clínicas futuras. No Capitulo 6, descreve-se a caracterização dos perfis metabólicos da urina (de um subgrupo de indivíduos) por cromatografia líquida de ultra-eficiência acoplada a espetrometria de massa (UPLC-MS). Embora não avançando muito na identificação estrutural de possíveis marcadores, este estudo reforçou o valor diagnóstico da urina, já que os modelos multivariados resultantes apresentaram taxa de classificação e poder preditivo elevados. Finalmente, no Capítulo 7, apresentam-se as principais conclusões deste trabalho, realçando o contributo da metabolómica integrada de tecidos e biofluidos para a compreensão do metabolismo alterado do cancro do pulmão e para a deteção de novos perfis marcadores com valor diagnóstico.
2

Miljanović, Nina [Verfasser], and Heidrun [Akademischer Betreuer] Potschka. "Proteomic and metabolomic signature of Dravet Syndrome : analysis in a genetic Scn1a-A1783V mouse model / Nina Miljanović ; Betreuer: Heidrun Potschka." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2021. http://d-nb.info/1239049420/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Chao, de la Barca Juan Manuel. "Approche métabolomique des maladies dégénératives de la rétine et du nerf optique. : neuropathie optique héréditaire de Leber, athropie optique dominante et préconditionnement rétinien induit par la lumière The metabolomic signature of Leber's hereditary optic neuropathy reveals endoplasmic reticulum stress Metabolic signature of remote ischemic preconditioning involving a cocktail of amino acids and biogenic amines." Thesis, Angers, 2016. http://www.theses.fr/2016ANGE0069.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Nous avons réalisé une approche métabolomique ciblée par spectrométrie de masse, avec quantification de 188 métabolites incluant des lipides et des molécules polaires. Trois processus physiopathologiques en rapport avec la rétine et le nerf optique ont été étudiés : la neuropathie optique héréditaire de Leber (NOHL), l’atrophie optique autosomique dominante (AOD) par haplo-insuffisance du gène OPA1 et le préconditionnement rétinien induit par la lumière (PRIL). Les principaux résultats sont : Projet NOHL : Le pool des acides aminés et la concentration de certaines sphingomyélines (SM) sont diminués tandis que la concentration de 10 phosphatidylcholines (PC) est augmentée dans les fibroblastes des porteurs d’une mutation de type NOH. Les fibroblastes des patients atteints d’une NOHL ont montré un stress du réticulum endoplasmique réversible pharmacologiquement. Projet AOD : Les variations dans la concentration de certains lipides, du glutamate et de quelques métabolites polaires neuroprotecteurs ont suggéré une altération de la myéline et une dysfonction métabolique axonale pré-symptomatique dans le nerf optique des souris Opa1+/-. Un dimorphisme sexuel a été observé dans le métabolome du nerf optique des souris. Projet PRIL : Le stimulus lumineux préconditionnant semble provoquer un accroissement de la protéolyse et une diminution du monoxyde d’azote dans la rétine. Le stress photique parait associé à un remodelage des lipides rétiniens. Un dimorphisme sexuel a été observé dans le métabolome rétinien des rats contrôles. Ces résultats montrent que l'approche métabolomique est pertinente pour l'étude physiopathologique des maladies oculaires
We have conducted a mass spectrometry targeted metabolomics approach, enabling us to quantify 188 metabolites including lipids and more polar molecules. Three condition related to the retina and the optic nerve have been studied: Leber hereditary optic neuropathy (LHON), dominant optic atrophy (DOA) due to OPA1 haploinsufficiency and retina light-induced preconditioning (RLIP). The main results we obtained are: LHON project: Concentrations of the whole pool of amino acid and some sphingomyelins (SM) were diminished whereas those of ten phosphatidylcholines (PC)were increased in fibroblasts carrying a LHON mutation. Fibroblasts from LHON-affected patients showed pharmacologically reversible endoplasmic reticulum stress. DOA project: Variations in the concentration of some lipids, glutamate and polar neuroprotective metabolites suggested pre-symptomatic alterations of the myelin sheath along with axonal metabolic dysfunction of the optic nerve in Opa1 +/-mice. A sexual dimorphism was also observed in the metabolome of the optic nerve. RLIP project: Preconditioning light seemed to elicit acute proteolysis and decreased NO production in the retina. Light stress was also related with lipid remodeling in the retina. A sexual dimorphism was also observed in the retina of control rats. Taken as a whole, our results show that the metabolomics approach is adapted and relevant for the study of the physiopathology of ocular diseases
4

Vives, Usano Marta 1990. "Prenatal and postnatal exposure to tobacco smoking and molecular signatures in children." Doctoral thesis, Universitat Pompeu Fabra, 2018. http://hdl.handle.net/10803/665799.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Maternal smoking during pregnancy (MSDP) and postnatal secondhand smoking (SHS) are ongoing public health concerns that are associated with adverse child health outcomes, but not much is known about the molecular mechanisms. We investigated the association between MSDP and placental DNA methylation, and its link with reproductive outcomes through a meta-analysis. We identified 1224 differentially methylated CpGs in placenta, which were enriched for pathways related to inflammation, growth factors and vascularization. Moreover, the methylation of many of these CpGs was associated with gestational age and birth size. We also investigated the association between MSDP and postnatal SHS, and different molecular layers in children: blood DNA methylation and transcription, plasma proteins, and serum and urinary metabolites. In utero exposure, was only associated with child DNA methylation, confirming a persistent MSDP-related signature on the blood epigenome. However, this imprint was not mirrored in the transcriptome. In contrast, postnatal SHS was related to protein and metabolite levels, which are more dynamic, and likely reflecting short-term exposures. Of note, the MSDP-associated methylome signature was tissue-specific.
Fumar durant l’embaràs i l’exposició a tabac passiu de manera postnatal són preocupacions en la salut pública que estan associades a conseqüències adverses en la salut infantil, però poc se sap sobre els mecanismes moleculars. Hem investigat l’associació entre fumar durant l’embaràs i la metilació de l’ADN placentari, i la seva relació amb les conseqüències reproductives a través d’un meta-anàlisi. Hem identificat 1224 CpGs diferencialment metilats a placenta, enriquits en vies relacionades amb inflamació, factors de creixement i vascularització. A més a més, la metilació de molts CpGs està associada a l’edat gestacional i les mides al naixement. Hem investigat també l’associació entre fumar durant l’embaràs i l’exposició a tabac passiu de manera postnatal, i diferents capes moleculars en nens: metilació de l’ADN i transcripció en sang, proteïnes en plasma, metabòlits en sèrum i orina. L’exposició uterina, estava només associada amb la metilació de l’ADN del nen, confirmant un efecte persistent del patró de l’epigenoma en sang. Tot i això, aquesta empremta no es veu reflectida en el transcriptoma. En canvi, l’exposició a tabac passiu estava relacionada amb proteïnes i metabòlits, que són més dinàmics, i reflecteixen efectes a més curt termini. Hem observat també que el patró de metilació és específic de teixit.
5

Lu, YongPing [Verfasser]. "Maternal and fetal metabolomic signatures in regard to birth outcome and gestational disease / YongPing Lu." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2018. http://d-nb.info/1176636332/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Knacke, Henrike [Verfasser], Nele [Akademischer Betreuer] Friedrich, Nele [Gutachter] Friedrich, and Martin [Gutachter] Reincke. "Metabolische Signaturen des Insulin-like growth factor 1 anhand von Metabolom-Untersuchungen in Plasma und Urin / Henrike Knacke ; Gutachter: Nele Friedrich, Martin Reincke ; Betreuer: Nele Friedrich." Greifswald : Universität Greifswald, 2019. http://d-nb.info/1202111297/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lecuyer, Lucie. "Signatures métabolomiques associées au risque à long terme de cancers du sein et de la prostate et à l’alimentation dans la cohorte SU.VI.MAX : Nouveaux horizons ouverts par la métabolomique appliquée à l’épidémiologie nutritionnelle." Thesis, Paris 13, 2019. http://www.theses.fr/2019PA131023.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Les cancers du sein et de la prostate sont parmi les cancers ayant la plus forte incidence dans le monde,notamment dans les pays occidentaux. Les principaux défis actuels sont d’améliorer la compréhension des relations nutrition/santé et l’identification des personnes à plus haut risque bien avant l’apparition du cancer afin de mettre en place des actions de préventions. De nombreux facteurs influencent la mise en place et la progression du cancer. Parmi eux, la nutrition apparaît comme un facteur clé, puisqu’il s’agit d’un facteur modifiable sur lequel il est possible d'agir via des interventions, il est donc essentiel d’évaluer sa contribution. Pour cela, une mesure précise de l'apport nutritionnel est nécessaire. La métabolomique permettant l’identification de potentiels biomarqueurs endogènes, exogènes et microbiens ouvre donc de nouvelles perspectives en épidémiologie nutritionnelle. A ce jour, encore très peu d’études ont investigué l’impact de l’alimentation globale sur le métabolisme et le risque de cancer du sein et de la prostate par profilage métabolomique. Dans le cadre de cette thèse, nous avons donc conduit des études cas-témoins nichées et transversales dans la cohorte SU.VI.MAX afin de mettre en évidence des signatures plasmatiques du risque de cancers du sein et de la prostate et de l’alimentation globale. Les échantillons plasmatiques ont été collectés à l’inclusion dans la cohorte et analysés par deux méthodes complémentaires : la spectrométrie de masse couplée à la chromatographie liquide et la résonance magnétique nucléaire du proton. Les habitudes alimentaires des participants ont été estimées grâce à des enregistrements alimentaires de 24h répétés et les données socio-démographiques et de mode de vie ont été obtenues grâce à des questionnaires autodéclarés. Ces recherches ont permis de mettre en évidence des métabolites endogènes et issus du métabolisme microbien associés à l’alimentation globale et également des biomarqueurs candidats d’une exposition alimentaire spécifique. Nous avons également identifié des métabolites associés au risque de cancers du sein et de la prostate, endogènes, exogènes et microbiens suggérant une perturbation métabolique jusqu’à 13 ans avant le diagnostic du cancer. Par ailleurs, l’alimentation semble jouer un rôle dans la variation des taux plasmatiques de certains métabolites permettant de discriminer les individus à plus haut risque de développer un cancer du sein ou de la prostate. Ces résultats devront être répliqués dans d’autres études indépendantes d’observation et d’intervention.A terme, l’identification de signatures métaboliques robustes du risque de cancers du sein et de la prostate, de l’impact de l’alimentation sur le métabolisme et la cancérogenèse et de l’apport alimentaire pourraient permettre de contribuer à l’amélioration de la compréhension des relations entre environnement et santé, de l’évaluation de l’exposition nutritionnelle voire à la mise en place de nouvelles recommandations en matière de santé publique en vue de la diminution de l’incidence de ces pathologies
Breast and prostate cancers are among the cancers with the highest incidence worldwide and notably in Western countries. The main current challenges lie in the improvement of understanding of nutrition/health relationships and in the identification of individuals at higher risk long before the development of overt cancer to set up prevention actions. A variety of factors exert an impact on the onset and progression of cancer. Among these, nutrition appears as a key factor, in that it can be modified and acted upon through interventions. It is therefore crucial to assess its contribution. For this purpose,detailed and accurate assessment of nutritional intake is essential. Metabolomics, allowing the identification of endogenous, exogenous and microbial biomarkers, opens new perspectives in nutritional epidemiology. So far, few have studies investigated the impact of overall diet on metabolism and risk of breast and prostate cancer through metabolomic profiling. As part of this thesis, we conducted nested case-controls and cross-sectional studies within the SU.VI.MAX cohort to highlight plasma signatures of breast and prostate cancer risks and of overall diet. Plasma samples were collected at baseline and were analysed using two complementary methods : mass spectrometry coupled with liquid chromatography and proton nuclear magnetic resonance. Participants dietary habits were estimated using repeated 24h dietary records and socio-demographic and lifestyle data were collected from self-administered questionnaires.These investigations highlighted endogenous and microbial metabolites associated with overall diet as well as candidate biomarkers of specific dietary exposures. We also identified endogenous, exogenous and microbial metabolites associated with breast and prostate cancers risk suggesting a metabolic disruption up to 13 years before cancer diagnostic. Furthermore, diet appears to be implicated in the variation in plasma levels of some metabolites discriminating individuals at higher risk of developing breast or prostate cancers. These results need to be replicated in future independent observational and interventional studies. In the future, the identification of robust metabolic signatures of breast and prostate cancers risk, of the impact of diet on metabolism and carcinogenesis, and food intake would contribute to better understand health and environment relationships, to better estimate nutritional exposure or even to contribute to the set-up of new public health recommendations in order to reduce the incidence of these pathologies
8

Moro, Joanna. "Impact de la déficience en acides aminés indispensables sur le métabolisme protéique et énergétique, et identification de signatures métaboliques." Thesis, université Paris-Saclay, 2021. http://www.theses.fr/2021UPASB001.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
La disponibilité de sources de protéines pour l’alimentation humaine est une préoccupation majeure du fait des transitions démographiques, économiques et nutritionnelles mondiales. Les apports en protéines doivent couvrir les besoins en neuf acides aminés considérés comme indispensables (AAI). Il est important que leur besoin soit couvert pour éviter des situations de déséquilibre du métabolisme protéique et énergétique. Différentes études ont été développées afin de déterminer ce besoin : bilan azoté, méthode factorielle, et méthodes utilisant les isotopes stables. Cependant, ces méthodes sont lourdes et invasives et les valeurs de besoins obtenues présentes des différences importantes. Il est donc nécessaire de développer des approches plus précises et non invasives, telle que la métabolomique, recommandée par la FAO. Les objectifs de cette thèse sont d’évaluer l’impact de la déficience en protéines et en AAI (lysine et thréonine) sur le métabolisme protéique et énergétique et d’identifier des marqueurs de la déficience de ces deux acides aminés chez le rat en croissance. Des niveaux sévères de déficience (85% ; 75%) en protéines et en lysine et thréonine diminuent le poids et la masse maigre et augmentent la prise alimentaire. Ces effets sont associés à une diminution de la synthèse protéique. et à une augmentation du métabolisme énergétique pour les faibles apports en protéines. Ces effets semblent médiés par FGF21. Les analyses de métabolomiques dans les urines révèlent que des variations du pipecolate et de la taurine signent respectivement une déficience en lysine et en thréonine
The availability of protein sources for human nutri-tion is a major concern due to global demographics, economics and nutritional transitions. Protein intakes must cover the need for nine indispensable amino acids (IAA). It is important that this need is met in order to avoid situations of protein and energy me-tabolism imbalance. Various studies have been de-veloped to determine this need: nitrogen balance, the factorial method, and methods using stable iso-topes. However, these methods are difficult and invasive, and the obtained values of needs present significant differences. It is therefore necessary to develop more precise and non-invasive approaches, such as metabolomics, as recommended by the FAO.The objectives of this thesis are to assess the impact of protein and IAA (lysine and threonine) deficiency on protein and energy metabolism and to identify markers of deficiency for these two amino acids in the growing rat. Severe levels of deficiency (85%; 75%) in protein and lysine and threonine decrease weight and lean mass and increase food intake. These effects are associated with a decrease in protein synthesis and an increase in energy metabolism in low protein diets. These effects seems to be mediated by FGF21. Analyses of metabolomics in urine show that variations in pipecolate and taurine indicate lysine and threonine deficiencies, respectively
9

Sakiou, Sofia. "Caractérisation, traçabilité et contrôle qualité des huiles essentielles de lavandes et de lavandins : Apports des signatures chromatographiques et spectroscopiques." Thesis, Aix-Marseille, 2015. http://www.theses.fr/2015AIXM4369/document.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Les huiles essentielles (HE) de lavande et de lavandin appartiennent au patrimoine de la région méditerranéenne. Comme tout produit naturel ou synthétique à valeur ajoutée, ces HE doivent être contrôlées pour justifier la qualité du produit. Ce contrôle qualité nécessite la mise en place d'une méthodologie analytique fiable. Dans cette étude, une nouvelle approche utilisant les techniques spectroscopiques et chromatographiques et le traitement de données à l'aide d'outils chimiométriques permet de différencier les HE de lavande et de lavandin par origine variétale. Cette discrimination s'effectue grâce à leur empreinte spectrale ou chromatographique. L’intérêt d’utiliser la chromatographie chirale associée à la détection polarimétrique et de la signature chiroptique acquise a également été étudié. Cette étude nous a permis d’identifier des marqueurs métabolomiques qui sont primordiaux pour caractériser les variétés. Les résultats montrent qu'il est possible de discriminer les HE de lavande et de lavandin selon leurs variétés avec une bonne justesse sur l'ensemble des techniques utilisées
Lavender and lavandin essential oils (EOs) belong to the heritage of the Mediterranean region. Like any natural or synthetic product with an added value, these EOs must be controlled to justify the quality of the product. This quality control requires the establishment of a reliable analytical methodology. In this study, a new approach using spectroscopic and chromatographic techniques for data processing associated to chemometric tools allows to discriminate lavender and lavandin EOs. This discrimination is carried out thanks to their spectroscopic or chromatographic fingerprints. The interest to use the chiral chromatography combined with polarimetric detection and of acquired chiroptical signature was also studied. This methodology has allowed us to identify metabolomic markers which are paramount to characterize the varieties. The results show that it is possible to discriminate the lavender and lavandin EOs according to their varieties with good accuracy on all of the techniques used
10

Pérez, lanzón María. "Modeling Hormone Receptor Positive Breast Cancer in Immunocompetent Mice Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression Organoids for Modeling Genetic Diseases. In: International Review of Cell and Molecular Biology A preclinical mouse model of osteosarcoma to define the extracellular vesicle-mediated communication between tumor and mesenchymal stem cells Failure of immunosurveillance accelerates aging The metabolomic signature of extreme longevity: Naked mole rats versus mice Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity Laminin-binding integrins are essential for the maintenance of functional mammary secretory epithelium in lactation Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer." Thesis, université Paris-Saclay, 2021. http://www.theses.fr/2021UPASL019.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Les progrès de la recherche sur le cancer du sein dépendent de la disponibilité d’outils appropriés, comme les lignées cellulaires qui peuvent être implantées chez des souris immunocompétentes. La souche de souris C57Bl/6 est la plus étudiée et c’est la seule pour laquelle certaines variantes génétiques sont disponibles. Étant donné qu'aucune lignée cellulaire de carcinome mammaire à récepteurs hormonaux positifs de souche C57Bl/6 n'est disponible, nous avons décidé d'établir des lignées cellulaires de ce type. Nous avons induit des cancers du sein chez des souris C57BL/6 femelles en utilisant un analogue synthétique de la progestérone combiné à un agent endommageant l'ADN. Des lignées cellulaires ont été établies à partir de ces tumeurs et sélectionnées pour leur positivité au niveau du double récepteur (estrogène + progestérone), ainsi que pour leur transplantabilité chez les femelles C57BL/6. Parmi plusieurs lignées, une lignée cellulaire, que nous avons appelée MD5, remplissait ces critères et a permis l'établissement de tumeurs mal différenciées et très prolifératives. Ces tumeurs ont réduit leur croissance (sans toutefois régresser) lors du traitement par des antagonistes des récepteurs d’œstrogènes, ainsi que par une chimiothérapie à base d'anthracylines. Cependant, ce dernier effet n'a pas été influencé par la déplétion des lymphocytes T et, en outre, ces tumeurs n'ont pas répondu au blocage de PD-1, ce qui suggère que les tumeurs MD5 sont immunologiquement froides. En conclusion, les cellules MD5, dérivées des animaux C57BL/6, constituent un modèle de cancer du sein à récepteurs hormonaux positifs de mauvais pronostic
Progress in breast cancer research relies on the availability of suitable cell lines that can be implanted in immunocompetent laboratory mice. The best explored mouse strain, C57Bl/6, is also the only one for which multiple genetic variants are available. Driven by the fact that no hormone receptor-positive C57Bl/6-derived mammary carcinoma cell lines are available, we decided to establish such cell lines. Breast cancers were induced in female C57BL/6 mice using a synthetic progesterone analogue combined with a DNA damaging agent. Cell lines were established from these tumors and selected for dual (estrogen + progesterone) receptor positivity, as well as transplantability into C57BL/6 females. One cell line, which we called MD5,fulfilled these criteria and allowed for the establishment of poorly differentiated, highly proliferative, immune cold tumors. Such tumors reduced their growth (though did not regress) upon treatment with estrogen receptor antagonists, as well as with anthracyline-based chemotherapy. However, the latter effect was not influenced by T cell depletion and MD tumors failed to respond to PD-1 blockade, suggesting that they are immunologically cold. In conclusion, C57BL/6-derived MD5 cells constitute a model of poor prognosis hormone receptor-positive breast cancer
Більше джерел

Книги з теми "Metabolomic signature":

1

Vermeulen, Roel, Douglas A. Bell, Dean P. Jones, Montserrat Garcia-Closas, Avrum Spira, Teresa W. Wang, Martyn T. Smith, Qing Lan, and Nathaniel Rothman. Application of Biomarkers in Cancer Epidemiology. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0006.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Advancements in OMICs are now enabling investigators to explore comprehensively the biological consequences of exogenous and endogenous exposures by detecting molecular signatures of exposure, early signs of adverse biological effects, preclinical disease, and molecularly defined cancer subtypes. These new technologies have proven invaluable for assembling a comprehensive portrait of human exposure, health, and disease. This includes hypothesis-driven biomarkers, as well as platforms that can agnostically analyze entire biologic processes and “compartments,” including the measurement of small molecules (metabolomics), DNA polymorphisms and rarer inherited variants (genomics), methylation and microRNA (epigenomics), chromosome-wide alterations, mRNA (transcriptomics), proteins (proteomics), and the microbiome (microbiomics). Although the implementation of these technologies in epidemiologic studies has already shown great promise, some challenges of particular importance must be addressed. Non-genetic OMIC markers vary over time due to both random variation and physiologic changes. Therefore, there is an urgent need for cohorts to collect repeat biological samples over time.

Частини книг з теми "Metabolomic signature":

1

Chalikiopoulou, Constantina, José Carlos Gómez-Tamayo, and Theodora Katsila. "Untargeted Metabolomics for Disease-Specific Signatures." In Mass Spectrometry for Metabolomics, 71–81. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2699-3_7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Balikcioglu, Pinar Gumus, and Christopher B. Newgard. "Metabolomic Signatures and Metabolic Complications in Childhood Obesity." In Contemporary Endocrinology, 343–61. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-68192-4_21.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Elolimy, Ahmed A., Mohamed Zeineldin, Mohamed Abdelmegeid, Alzahraa M. Abdelatty, Abdulrahman S. Alharthi, Mohammed H. Bakr, Mona M. M. Y. Elghandour, Abdelfattah Z. M. Salem, and Juan J. Loor. "Metabolomics and Proteomics Signatures in Feed-Efficient Beef and Dairy Cattle." In Sustainable Agriculture Reviews, 153–65. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76529-3_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Czajkowska, Anna, Ahsan Hameed, Mauro Galli, Muhammad Umair Ijaz, Adam Kretowski, and Michal Ciborowski. "Altered Metabolome of Amino Acids Species: A Source of Signature Early Biomarkers of T2DM." In Biomarkers in Diabetes, 83–125. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08014-2_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Czajkowska, Anna, Ahsan Hameed, Mauro Galli, Muhammad Umair Ijaz, Adam Kretowski, and Michal Ciborowski. "Altered Metabolome of Amino Acids Species: A Source of Signature Early Biomarkers of T2DM." In Biomarkers in Diabetes, 1–44. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-81303-1_5-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

"Metabolomics and the Personalized Metabolic Signature." In Personalized Nutrition, 39–48. CRC Press, 2007. http://dx.doi.org/10.1201/9781420009170-9.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Gibney, Michael, Marianne Walsh, and Lorraine Brennan. "Metabolomics and the Personalized Metabolic Signature." In Personalized Nutrition, 23–32. CRC Press, 2007. http://dx.doi.org/10.1201/9781420009170.ch3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Suman, Ray. "Proteomics and metabolomics in neuropsychiatry." In Oxford Textbook of Neuropsychiatry, edited by Niruj Agrawal, Rafey Faruqui, and Mayur Bodani, 105–14. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198757139.003.0010.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Accurate diagnosis and treatment of neuropsychiatric diseases, such as Alzheimer’s disease, schizophrenia, bipolar disorder, depression, stress, and anxiety, are often complicated by aetiological and clinical heterogeneity. There is a need for a greater range of diagnostic tools for early detection of such disorders. This can help with improved prediction of forthcoming disease, diagnostic precision, disease severity description, and improved treatment choice. The metabolic changes in various disease states can be captured using metabolomics, an approach that may often have pre-clinical biomarkers of neurological diseases. Proteomic technologies, which are based on mass spectrometry techniques, hold great promise in investigating disease-specific protein signatures of psychiatric disorders. It is hoped that proteomics and metabolomics will allow researchers and clinicians to study neuropsychiatric disorders in new ways and enable new discoveries to be made. This chapter focuses on the role of proteomics and metabolomics in neuropsychiatry research.
9

Arjmand, Babak, Sepideh Alavi-Moghadam, Peyvand Parhizkar-Roudsari, Mostafa Rezaei-Tavirani, Akram Tayanloo-Beik, Parisa Goodarzi, Neda Mehrdad, Fereshteh Mohamadi-Jahani, and Bagher Larijani. "Metabolomics Signatures of SARS-CoV-2 Infection." In Advances in Experimental Medicine and Biology. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/5584_2021_674.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Niharika, Pedamallu, S. Manohar Babu, A. Mercy, Akula Prabhu Sangeetha, and Satya Narayan Tripathy. "MULTI-OMICS TECHNOLOGY BASED BIOMARKERS." In Futuristic Trends in Biotechnology Volume 2 Book 27, 225–33. Iterative International Publishers, Selfypage Developers Pvt Ltd, 2023. http://dx.doi.org/10.58532/v2bs27p2ch6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Multi-omics techniques, which assimilate data from genomics (DNA), transcriptomics (RNA), proteomics (proteins), and metabolomics (metabolites) are useful in investigation of oncogenesis pathways. High-throughput omics technologies have accelerated the identification of numerous potential biomarkers in recent years. An overview of the current state in this domain is offered with examples of genomics, proteomics, transcriptomics, metabolomics and microbiomics biomarkers in the field of oncology, along with some proposed ways to accelerate their validation. The utilization of multi-omics data has enhanced our understanding of the disease and enabled the identification of valuable biomarkers. These molecular signatures are helpful for elucidating the development and progression of cancer and any disease. In this chapter, efforts are made to emphasize potential applications of multi-omics for finding novel biomarkers and enhancing clinical evaluation

Тези доповідей конференцій з теми "Metabolomic signature":

1

González-Domínguez, Raúl, Álvaro González-Domínguez, and Alfonso Lechuga-Sancho. "Comparison of the metabolomic signature of diabetes and the oral glucose tolerance test." In 4th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2018. http://dx.doi.org/10.3390/ecmc-4-05571.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Onesti, Concetta Elisa, François Boemer, Claire Josse, Ahmed Debit, Christophe Poulet, Vincent Bours, and Guy Jerusalem. "Abstract PS17-01: A metabolomic signature as screening method for breast cancer diagnosis." In Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.sabcs20-ps17-01.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Selvaraj, Emmanuel, Daniel Radford-Smith, Rory Peters, Kate Lynch, Daniel Anthony, Michael Pavlides, Alessandra Geremia, Adam Bailey, Emma Culver, and Fay Probert. "O04 Serum nuclear magnetic resonance metabolomic signature can discriminate immunoglobulin G4-related sclerosing cholangitis and primary sclerosing cholangitis." In Abstracts of the British Association for the Study of the Liver Annual Meeting, 22–24 November 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-basl.4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Liu, Zhongbo, Christopher A. Blair, and Xiaolin Zi. "Abstract 4867: The metabolomic signature of Rhodiola rosea L. extracts- (SHR-5) treated mouse bladder cancer in the UPII-mutant Ha-ras transgenic model." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4867.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Moore, A. R., X. Song, J. Roque, C. Perez, S. Battu, R. Vojnik, J. Wilson, J. E. Levitt, R. Zare, and A. Rogers. "A Lung-specific Metabolic Signature From Heat and Moisture Exchange (HME) Filter Metabolomic Analysis Is Distinct From Plasma Signal in Acute Respiratory Distress Syndrome." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7210.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Wong, K., I. Sulaiman, B. G. Wu, B. Kwok, C. R. Barnett, Y. Li, A. Tsirigos, et al. "Metabolomic Signatures in Mild COPD." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5722.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Hourmozdi, J., P. J. Leary, D. D. Ralph, S. J. Nolley, S. G. Rayner, and S. A. Gharib. "Peripheral Blood Metabolomic Signatures Associated with Mortality in Pulmonary Hypertension." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6353.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Labaki, W., Y. Wang, S. Murray, J. Curtis, R. Bowler, C. Pistenmaa, P. Nardelli, et al. "Differentiating metabolomic signatures of airway and pulmonary vascular abnormalities in COPD." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2448.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Gaul, David A., Christina M. Jones, Maria Eugenia Monge, Long Q. Tran, Martin M. Matzuk, John F. McDonald, and Facundo M. Fernandez. "Abstract AS05: Metabolomic signatures in sera from early stage ovarian cancer patients." In Abstracts: 10th Biennial Ovarian Cancer Research Symposium; September 8-9, 2014; Seattle, WA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.ovcasymp14-as05.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Pi, H., L. Xia, D. D. Ralph, S. G. Rayner, A. Shojaie, P. J. Leary, and S. A. Gharib. "Metabolomic Signatures Associated with Right Ventricular Dilation and Mortality in Pulmonary Arterial Hypertension." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3442.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

До бібліографії